Results 91 to 100 of about 17,630,315 (317)

TIM-3 Rs10515746 (A/C) and Rs10053538 (C/A) Gene Polymorphisms and Risk of Multiple Sclerosis

open access: yesIranian Journal of Public Health, 2016
Background: Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) caused by autoreactive T cells against myelin antigens.
Esmat YAGHOOBI   +3 more
doaj  

Blocking Tim-3 enhances the anti-tumor immunity of STING agonist ADU-S100 by unleashing CD4+ T cells through regulating type 2 conventional dendritic cells

open access: yesTheranostics, 2023
Rationale: An immunosuppressive tumor microenvironment (TME) is a major obstacle in tumor immunotherapy. Stimulator of interferon genes (STING) agonists trigger an inflammatory innate immune response to potentially overcome tumor immunosuppression. While
Jing Luo   +11 more
semanticscholar   +1 more source

Psychosocial Outcomes in Patients With Endocrine Tumor Syndromes: A Systematic Review

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Introduction The combination of disease manifestations, the familial burden, and varying penetrance of endocrine tumor syndromes (ETSs) is unique. This review aimed to portray and summarize available data on psychosocial outcomes in patients with ETSs and explore gaps and opportunities for future research and care.
Daniël Zwerus   +6 more
wiley   +1 more source

Increased bovine Tim-3 and its ligand expressions during bovine leukemia virus infection

open access: yesVeterinary Research, 2012
The immunoinhibitory receptor T cell immunoglobulin domain and mucin domain-3 (Tim-3) and its ligand, galectin-9 (Gal-9), are involved in the immune evasion mechanisms for several pathogens causing chronic infections.
Okagawa Tomohiro   +8 more
doaj   +1 more source

QUANTITATIVE EXPRESSION FEATURES OF PD-1 AND TIM-3 CHECKPOINT MOLECULE RECEPTORS ON CD4⁺ AND CD8⁺ T-CELLS IN BREAST CANCER OF VARYING PROGRESSION DEGREES

open access: yesМедицинская иммунология, 2021
During the course of chronic viral infections or tumor growth, due to the constant presence of antigen and inflammation, a dysfunctional state of T-cells called exhaustion occurs.
Yu. A. Shevchenko   +6 more
doaj   +1 more source

Activated Tim-3/Galectin-9 participated in the development of multiple myeloma by negatively regulating CD4 T cells

open access: yesHematology, 2023
The interaction between Tim-3 on T cells and its ligand Galectin-9 negatively regulates the cellular immune response. However, the regulation of Tim-3/Galectin-9 on CD4 T cell subsets in multiple myeloma (MM) remains unclear. The aim of this study was to
Rui Zhang   +4 more
semanticscholar   +1 more source

Memory NK cell features exploitable in anticancer immunotherapy [PDF]

open access: yes, 2019
Besides their innate ability to rapidly produce effector cytokines and kill virus-infected or transformed cells, natural killer (NK) cells display a strong capability to adapt to environmental modifications and to differentiate into long-lived ...
Battella, Simone   +5 more
core   +2 more sources

Nutritional and Behavioral Intervention for Long‐Term Childhood Acute Leukemia Survivors With Metabolic Syndrome

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Purpose Metabolic syndrome (MetS) is a common complication in survivors of childhood acute lymphoblastic and myeloid leukemia (AL), and a major risk factor for premature cardiovascular disease, type‐2‐diabetes, and metabolic dysfunction‐associated steatotic liver disease (MASLD).
Visentin Sandrine   +10 more
wiley   +1 more source

CULLIN-3 controls TIMELESS oscillations in the Drosophila circadian clock. [PDF]

open access: yesPLoS Biology, 2012
Eukaryotic circadian clocks rely on transcriptional feedback loops. In Drosophila, the PERIOD (PER) and TIMELESS (TIM) proteins accumulate during the night, inhibit the activity of the CLOCK (CLK)/CYCLE (CYC) transcriptional complex, and are degraded in ...
Brigitte Grima   +4 more
doaj   +1 more source

TIM-3, LAG-3, or 2B4 gene disruptions increase the anti-tumor response of engineered T cells

open access: yesFrontiers in Immunology
Background In adoptive T cell therapy, the long term therapeutic benefits in patients treated with engineered tumor specific T cells are limited by the lack of long term persistence of the infused cellular products and by the immunosuppressive mechanisms
B. Cianciotti   +19 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy